Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway

ANAVEX LIFE SCIENCES CORP.

2024-Q2 EPS reported -$0.23

Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.
Cash and equivalents $139.4M at Mar 31, 2024; estimated ~4-year runway at current burn rate.
R&D expenses $9.7M, G&A $2.8M; no revenue as clinical-stage biopharma.
Marketing Authorisation application for blarcamesine (Alzheimer's) submitted to EMA; FDA guidance supports single cognitive endpoint.
First cohort fully enrolled in ANAVEX3-71 Phase 2 schizophrenia trial; Phase 2b/3 Alzheimer's data to be published.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

ANAVEX LIFE SCIENCES CORP. reported financial results for its fiscal quarter ended March 31, 2024.

Period: its fiscal quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Anavex Life Sciences Corp. (the “ Company ”) issued a press release reporting financial results for its fiscal quarter ended March 31, 2024

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

ANAVEX LIFE SCIENCES CORP. filing history →

Source: SEC EDGAR

accession 0001731122-24-000758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.